On the public citation graph

Therapeutic Monitoring of Calcineurin Inhibitors for the Nephrologist

0 signed · 357 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/bjs.4134openalex-snapshot

Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis

inferredcites →https://doi.org/10.1007/s001470050492openalex-snapshot

Prospective randomised study comparing tacrolimus (Prograf) and cyclosporin (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases

inferredcites →https://doi.org/10.1007/s00228-004-0774-8openalex-snapshot

Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients

inferredcites →https://doi.org/10.1016/0009-9120(95)00037-3openalex-snapshot

Alternative cyclosporine metabolic pathways and toxicity

inferredcites →https://doi.org/10.1016/0009-9236(95)90212-0openalex-snapshot

Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients*

inferredcites →https://doi.org/10.1016/j.healun.2003.08.032openalex-snapshot

Cyclosporine C2 monitoring improves renal dysfunction after lung transplantation

inferredcites →https://doi.org/10.1016/j.healun.2004.12.112openalex-snapshot

Best Single Time Points to Predict the Area-Under-the-Curve in Long-Term Heart Transplant Patients Taking Mycophenolate Mofetil in Combination with Cyclosporine or Tacrolimus

inferredcites →https://doi.org/10.1016/j.transproceed.2003.08.020openalex-snapshot

Tacrolimus monitoring by simplified sparse sampling under the concentration time curve

inferredcites →https://doi.org/10.1016/j.transproceed.2004.12.017openalex-snapshot

Prospective, Multicenter, Randomized Trial to Compare Incidence of New-Onset Diabetes Mellitus and Glucose Metabolism in Patients Receiving Cyclosporine Microemulsion Versus Tacrolimus After De Novo Kidney Transplantation

inferredcites →https://doi.org/10.1016/j.transproceed.2004.12.222openalex-snapshot

Conversion of Stable Kidney Transplant Recipients From a Twice Daily Prograf-Based Regimen to a Once Daily Modified Release Tacrolimus-Based Regimen

inferredcites →https://doi.org/10.1016/j.transproceed.2006.07.004openalex-snapshot

Comparison of Generic Cyclosporine Microemulsion versus Neoral in de Novo Renal Transplant Recipients Managed By 2-Hour Postdose Monitoring

inferredcites →https://doi.org/10.1016/s0009-9120(98)00049-6openalex-snapshot

Therapeutic drug monitoring of cyclosporine and tacrolimus

inferredcites →https://doi.org/10.1016/s0041-1345(00)00864-2openalex-snapshot

Pharmacokinetic validation of neoral absorption profiling

inferredcites →https://doi.org/10.1016/s0041-1345(00)01413-5openalex-snapshot

Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients

inferredcites →https://doi.org/10.1016/s0041-1345(00)02471-4openalex-snapshot

Canadian multicentre trial of tacrolimus/azathioprine/steroids versus tacrolimus/mycophenolate mofetil/steroids versus neoral/mycophenolate mofetil/steroids in renal transplantation

inferredcites →https://doi.org/10.1016/s0041-1345(01)02336-3openalex-snapshot

C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients

inferredcites →https://doi.org/10.1016/s0041-1345(03)00210-0openalex-snapshot

Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients

inferredcites →https://doi.org/10.1016/s0041-1345(98)00238-3openalex-snapshot

Effect of Breakfast on the Oral Bioavailability of Tacrolimus and Changes in Pharmacokinetics at Different Times Posttransplant in Renal Transplant Recipients

inferredcites →https://doi.org/10.1016/s0041-1345(98)00275-9openalex-snapshot

Demographic Considerations in Tacrolimus Pharmacokinetics

inferredcites →https://doi.org/10.1016/s0041-1345(98)01633-9openalex-snapshot

Low systemic exposure to tacrolimus correlates with acute rejection

inferredcites →https://doi.org/10.1016/s0140-6736(00)02480-6openalex-snapshot

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

inferredcites →https://doi.org/10.1016/s0140-6736(02)07875-3openalex-snapshot

Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study

inferredcites →https://doi.org/10.1016/s0140-6736(04)16808-6openalex-snapshot

Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial

inferredcites →https://doi.org/10.1016/s0140-6736(79)92440-1openalex-snapshot

CYCLOSPORIN A INITIALLY AS THE ONLY IMMUNOSUPPRESSANT IN 34 RECIPIENTS OF CADAVERIC ORGANS: 32 KIDNEYS, 2 PANCREASES, AND 2 LIVERS

inferredcites →https://doi.org/10.1016/s0140-6736(81)91971-1openalex-snapshot

IMMUNOLOGICAL AND PHARMACOLOGICAL MONITORING IN THE CLINICAL USE OF CYCLOSPORIN A

inferredcites →https://doi.org/10.1016/s0140-6736(97)08496-1openalex-snapshot

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens

inferredcites →https://doi.org/10.1016/s0272-6386(00)70013-8openalex-snapshot

Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients

inferredcites →https://doi.org/10.1034/j.1399-0012.2002.02036.xopenalex-snapshot

Two‐hour post‐dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts

inferredcites →https://doi.org/10.1034/j.1399-0012.2003.00038.xopenalex-snapshot

The use of an anti‐CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low‐dose tacrolimus and early withdrawal of steroids in renal transplant recipients

inferredcites →https://doi.org/10.1034/j.1600-6143.2002.020206.xopenalex-snapshot

Cyclosporine Microemulsion (Neoral®) Absorption Profiling and Sparse-sample Predictors During the First 3 Months after Renal Transplantation

inferredcites →https://doi.org/10.1034/j.1600-6143.2002.020207.xopenalex-snapshot

Randomized, International Study of Cyclosporine Microemulsion Absorption Profiling in Renal Transplantation with Basiliximab Immunoprophylaxis

inferredcites →https://doi.org/10.1034/j.1600-6143.2002.20814.xopenalex-snapshot

Adequate Early Cyclosporin Exposure is Critical to Prevent Renal Allograft Rejection: Patients Monitored by Absorption Profiling

inferredcites →https://doi.org/10.1034/j.1600-6143.2003.00005.xopenalex-snapshot

Multicenter Randomized Prospective Trial of Steroid Withdrawal in Renal Transplant Recipients Receiving Basiliximab, Cyclosporine Microemulsion and Mycophenolate Mofetil

inferredcites →https://doi.org/10.1038/clpt.1993.132openalex-snapshot

Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation

inferredcites →https://doi.org/10.1046/j.1365-2168.2000.01577.xopenalex-snapshot

Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants

inferredcites →https://doi.org/10.1046/j.1523-1755.1998.00042.xopenalex-snapshot

Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation

inferredcites →https://doi.org/10.1056/nejm198409133111103openalex-snapshot

Cyclosporine-Associated Chronic Nephropathy

inferredcites →https://doi.org/10.1093/clinchem/45.9.1477openalex-snapshot

Inhibition of Stimulated Interleukin-2 Production in Whole Blood: A Practical Measure of Cyclosporine Effect

inferredcites →https://doi.org/10.1093/clinchem/48.12.2225openalex-snapshot

Delayed Cytokine mRNA Expression Kinetics after T-Lymphocyte Costimulation: A Quantitative Measure of the Efficacy of Cyclosporin A-based Immunosuppression

inferredcites →https://doi.org/10.1093/ndt/gfg1029openalex-snapshot

Pharmacokinetics of tacrolimus-based combination therapies

inferredcites →https://doi.org/10.1093/ndt/gfh739openalex-snapshot

Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results

inferredcites →https://doi.org/10.1097/00007890-198508000-00013openalex-snapshot

THE EFFECT OF FOOD ON CYCLOSPORINE ABSORPTION

inferredcites →https://doi.org/10.1097/00007890-198511000-00001openalex-snapshot

INDIVIDUALIZATION OF CYCLOSPORINE THERAPY USING PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS

inferredcites →https://doi.org/10.1097/00007890-198811000-00017openalex-snapshot

THE RELATIONSHIP BETWEEN CYCLOSPORINE PHARMACOKINETIC PARAMETERS AND SUBSEQUENT ACUTE REJECTION IN RENAL TRANSPLANT RECIPIENTS

inferredcites →https://doi.org/10.1097/00007890-199409000-00004openalex-snapshot

CYCLOSPORINE PHARMACOKINETICS AND VARIABILITY FROM A MICROEMULSION FORMULATION—A MULTICENTER INVESTIGATION IN KIDNEY TRANSPLANT PATIENTS

inferredcites →https://doi.org/10.1097/00007890-199502270-00011openalex-snapshot

REDUCED INTER- AND INTRASUBJECT VARIABILITY IN CYCLOSPORINE PHARMACOKINETICS IN RENAL TRANSPLANT RECIPIENTS TREATED WITH A MICROEMULSION FORMULATION IN CONJUNCTION WITH FASTING, LOW-FAT MEALS, OR HIGH-FAT MEALS1,2

inferredcites →https://doi.org/10.1097/00007890-199603270-00005openalex-snapshot

THE PHARMACOKINETICS OF A MICROEMULSION FORMULATION OF CYCLOSPORINE IN PRIMARY RENAL ALLOGRAFT RECIPIENTS1

inferredcites →https://doi.org/10.1097/00007890-199603270-00021openalex-snapshot

THE SAFETY AND TOLERABILITY OF CYCLOSPORINE EMULSION VERSUS CYCLOSPORINE IN A RANDOMIZED, DOUBLE-BLIND COMPARISON IN PRIMARY RENAL ALLOGRAFT RECIPIENTS1

inferredcites →https://doi.org/10.1097/00007890-199609150-00010openalex-snapshot

VARIABLE ORAL ABSORPTION OF CYCLOSPORINE

inferredcites →https://doi.org/10.1097/00007890-199610150-00009openalex-snapshot

RELATIONSHIP OF FK506 WHOLE BLOOD CONCENTRATIONS AND EFFICACY AND TOXICITY AFTER LIVER AND KIDNEY TRANSPLANTATION

inferredcites →https://doi.org/10.1097/00007890-199612270-00009openalex-snapshot

A RANDOMIZED, PROSPECTIVE MULTICENTER PHARMACOEPIDEMIOLOGIC STUDY OF CYCLOSPORINE MICROEMULSION IN STABLE RENAL GRAFT RECIPIENTS1,2,3

inferredcites →https://doi.org/10.1097/00007890-199704150-00013openalex-snapshot

A COMPARISON OF TACROLIMUS (FK506) AND CYCLOSPORINE FOR IMMUNOSUPPRESSION AFTER CADAVERIC RENAL TRANSPLANTATION1

inferredcites →https://doi.org/10.1097/00007890-199708150-00012openalex-snapshot

MULTICENTER RANDOMIZED TRIAL COMPARING TACROLIMUS (FK506) AND CYCLOSPORINE IN THE PREVENTION OF RENAL ALLOGRAFT REJECTION1

inferredcites →https://doi.org/10.1097/00007890-199802270-00009openalex-snapshot

SAFETY AND TOLERABILITY OF CYCLOSPORINE AND CYCLOSPORINE MICROEMULSION DURING 18 MONTHS OF FOLLOW-UP IN STABLE RENAL TRANSPLANT RECIPIENTS

inferredcites →https://doi.org/10.1097/00007890-199812270-00009openalex-snapshot

COMPARISON OF NEORAL DOSE MONITORING WITH CYCLOSPORINE TROUGH LEVELS VERSUS 2-HR POSTDOSE LEVELS IN STABLE LIVER TRANSPLANT PATIENTS1,2

inferredcites →https://doi.org/10.1097/00007890-199907150-00011openalex-snapshot

NEORAL MONITORING BY SIMPLIFIED SPARSE SAMPLING AREA UNDER THE CONCENTRATION-TIME CURVE

inferredcites →https://doi.org/10.1097/00007890-199911150-00023openalex-snapshot

THE TEMPORAL PROFILE OF CALCINEURIN INHIBITION BY CYCLOSPORINE IN VIVO1

inferredcites →https://doi.org/10.1097/00007890-200002150-00022openalex-snapshot

STIMULATED RESPONSE OF PERIPHERAL LYMPHOCYTES MAY DISTINGUISH CYCLOSPORINE EFFECT IN RENAL TRANSPLANT RECIPIENTS RECEIVING A CYCLOSPORINE+RAPAMYCIN REGIMEN1

inferredcites →https://doi.org/10.1097/00007890-200011150-00015openalex-snapshot

DOUBLE-BLIND COMPARISON OF TWO CORTICOSTEROID REGIMENS PLUS MYCOPHENOLATE MOFETIL AND CYCLOSPORINE FOR PREVENTION OF ACUTE RENAL ALLOGRAFT REJECTION1

inferredcites →https://doi.org/10.1097/00007890-200101270-00019openalex-snapshot

A WORLDWIDE, PHASE III, RANDOMIZED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A SIROLIMUS/CYCLOSPORINE REGIMEN FOR PREVENTION OF ACUTE REJECTION IN RECIPIENTS OF PRIMARY MISMATCHED RENAL ALLOGRAFTS

inferredcites →https://doi.org/10.1097/00007890-200205151-00003openalex-snapshot

Patient management by Neoral C2 monitoring: An international consensus statement1

inferredcites →https://doi.org/10.1097/00007890-200407271-01224openalex-snapshot

RESULTS OF A THREE-YEAR PROSPECTIVE STUDY OF NEORAL C2 MONITORING IN LONG-TERM RENAL TRANSPLANT PATIENTS

inferredcites →https://doi.org/10.1097/01.ftd.0000158080.61201.65openalex-snapshot

Evaluation of a Limited Sampling Strategy to Estimate Area Under the Curve of Tacrolimus in Adult Renal Transplant Patients

inferredcites →https://doi.org/10.1097/01.tp.0000056635.59888.efopenalex-snapshot

A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients1

inferredcites →https://doi.org/10.1097/01.tp.0000061606.64917.beopenalex-snapshot

A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation

inferredcites →https://doi.org/10.1097/01.tp.0000068868.01424.61openalex-snapshot

Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients1

inferredcites →https://doi.org/10.1097/01.tp.0000085046.39523.d5openalex-snapshot

C2 monitoring in maintenance renal transplant recipients: is it worthwhile?

inferredcites →https://doi.org/10.1097/01.tp.0000089006.00653.64openalex-snapshot

Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion

inferredcites →https://doi.org/10.1097/01.tp.0000129095.51031.42openalex-snapshot

RESULTS OF LIS2T, A MULTICENTER, RANDOMIZED STUDY COMPARING CYCLOSPORINE MICROEMULSION WITH C2 MONITORING AND TACROLIMUS WITH C0 MONITORING IN DE NOVO LIVER TRANSPLANTATION

inferredcites →https://doi.org/10.1097/01.tp.0000137423.01887.7dopenalex-snapshot

Cyclosporine Minimization and Cost Reduction in Renal Transplant Recipients Receiving a C2-Monitored, Cyclosporine-Based Quadruple Immunosuppressive Regimen

inferredcites →https://doi.org/10.1097/01.tp.0000140486.97461.49openalex-snapshot

Everolimus and Reduced-Exposure Cyclosporine in de novo Renal-Transplant Recipients: A Three-Year Phase II, Randomized, Multicenter, Open-Label Study

inferredcites →https://doi.org/10.1097/01.tp.0000153158.91683.34openalex-snapshot

Efficacy and Safety Outcomes Among De Novo Renal Transplant Recipients Managed by C2 Monitoring of Cyclosporine A Microemulsion: Results of a 12-Month, Randomized, Multicenter Study

inferredcites →https://doi.org/10.1097/01.tp.0000154915.20524.0aopenalex-snapshot

Corticosteroid-Free Immunosuppression with Tacrolimus, Mycophenolate Mofetil, and Daclizumab Induction in Renal Transplantation

inferredcites →https://doi.org/10.1097/01.tp.0000156931.45209.e8openalex-snapshot

Results of a Three-Year Prospective Study of C2 Monitoring in Long-Term Renal Transplant Recipients Receiving Cyclosporine Microemulsion

inferredcites →https://doi.org/10.1097/01.tp.0000162980.68628.5aopenalex-snapshot

A Randomized, Prospective, Pharmacoeconomic Trial of Tacrolimus versus Cyclosporine in Combination with Thymoglobulin in Renal Transplant Recipients

inferredcites →https://doi.org/10.1097/01.tp.0000164352.65613.24openalex-snapshot

Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III Study

inferredcites →https://doi.org/10.1097/01.tp.0000181198.98232.0copenalex-snapshot

Assessment of the Bioequivalence of a Generic Cyclosporine A by a Randomized Controlled Trial in Stable Renal Recipients

inferredcites →https://doi.org/10.1097/01.tp.0000188688.15639.03openalex-snapshot

Does Bioequivalence Between Modified Cyclosporine Formulations Translate into Equal Outcomes?

inferredcites →https://doi.org/10.1097/01.tp.0000202880.78509.b4openalex-snapshot

Improved Renal Function after Conversion from Tacrolimus/Sirolimus to Tacrolimus/Mycophenolate Mofetil in Kidney Transplant Recipients

inferredcites →https://doi.org/10.1097/01.tp.0000203894.53714.27openalex-snapshot

A Randomized Long-Term Trial of Tacrolimus/Sirolimus versus Tacrolimums/Mycophenolate versus Cyclosporine/Sirolimus in Renal Transplantation: Three-Year Analysis

inferredcites →https://doi.org/10.1097/01.tp.0000239313.83735.33openalex-snapshot

A Comparison of the Effects of C2-Cyclosporine and C0-Tacrolimus on Renal Function and Cardiovascular Risk Factors in Kidney Transplant Recipients

inferredcites →https://doi.org/10.1097/01.tp.0000243358.75863.57openalex-snapshot

Pharmacodynamic Monitoring of Cyclosporine A in Renal Allograft Recipients Shows a Quantitative Relationship Between Immunosuppression and the Occurrence of Recurrent Infections and Malignancies

inferredcites →https://doi.org/10.1111/j.1399-0012.2005.00325.xopenalex-snapshot

Basiliximab lowers the cyclosporine therapeutic threshold in the early post‐kidney transplant period

inferredcites →https://doi.org/10.1111/j.1399-0012.2005.00331.xopenalex-snapshot

Concentration‐controlled use of sirolimus associated with reduced exposure of cyclosporine in black recipients of primarily living renal allograft donors: 12‐month results

inferredcites →https://doi.org/10.1111/j.1399-0012.2005.00369.xopenalex-snapshot

Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial

inferredcites →https://doi.org/10.1111/j.1399-0012.2005.00483.xopenalex-snapshot

The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function

inferredcites →https://doi.org/10.1111/j.1399-0012.2006.00605.xopenalex-snapshot

Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation

inferredcites →https://doi.org/10.1111/j.1432-2277.2004.00001.xopenalex-snapshot

C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients

inferredcites →https://doi.org/10.1111/j.1432-2277.2004.00039.xopenalex-snapshot

Clinical application of sirolimus in renal transplantation: an update

inferredcites →https://doi.org/10.1111/j.1432-2277.2006.00303.xopenalex-snapshot

Steroid withdrawal in living donor renal transplant recipients using tacrolimus and cyclosporine: a randomized prospective study*

inferredcites →https://doi.org/10.1111/j.1523-1755.2005.00352.xopenalex-snapshot

AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients

inferredcites →https://doi.org/10.1111/j.1600-6143.2004.00389.xopenalex-snapshot

Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6-Month Safety and Efficacy Results of Two Randomized Studies

inferredcites →https://doi.org/10.1111/j.1600-6143.2004.00419.xopenalex-snapshot

Steroid-Withdrawal at 3 Days After Renal Transplantation with Anti-IL-2 Receptor α Therapy: A Prospective, Randomized, Multicenter Study

inferredcites →https://doi.org/10.1111/j.1600-6143.2004.00624.xopenalex-snapshot

Sirolimus with Neoral Versus Mycophenolate Mofetil with Neoral is Associated with Decreased Renal Allograft Survival

inferredcites →https://doi.org/10.1111/j.1600-6143.2005.00742.xopenalex-snapshot

Incidence of BK with Tacrolimus Versus Cyclosporine and Impact of Preemptive Immunosuppression Reduction

inferredcites →https://doi.org/10.1111/j.1600-6143.2005.01019.xopenalex-snapshot

Sirolimus in Combination with Tacrolimus Is Associated with Worse Renal Allograft Survival Compared to Mycophenolate Mofetil Combined with Tacrolimus

inferredcites →https://doi.org/10.1111/j.1600-6143.2005.01063.xopenalex-snapshot

Three‐Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients

inferredcites →https://doi.org/10.1111/j.1600-6143.2005.01193.xopenalex-snapshot

Tacrolimus Combined with Two Different Dosagesof Sirolimus in Kidney Transplantation: Results of a Multicenter Study

inferredcites →https://doi.org/10.1136/bmj.38569.471007.aeopenalex-snapshot

Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data

inferredcites →https://doi.org/10.1681/asn.2005030249openalex-snapshot

No Difference in Degree of Interstitial Sirius Red–Stained Area in Serial Biopsies from Area under Concentration-over-Time Curves–Guided Cyclosporine versus Tacrolimus-Treated Renal Transplant Recipients at One Year

inferredcites →https://doi.org/10.1681/asn.2005080891openalex-snapshot

Molecular Comparison of Calcineurin Inhibitor–Induced Fibrogenic Responses in Protocol Renal Transplant Biopsies

inferredcites →https://doi.org/10.1681/asn.v124828openalex-snapshot

Approaching the Therapeutic Window for Cyclosporine in Kidney Transplantation

inferredcites →https://doi.org/10.2165/00003495-200161130-00006openalex-snapshot

Cyclosporin

inferredcites →https://doi.org/10.2165/00003495-200363120-00006openalex-snapshot

Tacrolimus

inferredcites →https://doi.org/10.2165/00019053-200422100-00001openalex-snapshot

An Economic Model of 2-Hour Post-Dose Ciclosporin Monitoring in Renal Transplantation

inferredcites →https://doi.org/10.2165/00063030-200115050-00001openalex-snapshot

C2 Monitoring Strategy for Optimising Cyclosporin Immunosuppression from the Neoral??* Formulation

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.2696477openalex-extracted

inferred← citeshttps://doi.org/10.2139/ssrn.3008030openalex-extracted

Data-Driven Management of Post-Transplant Medications: An APOMDP Approach

inferred← citeshttps://doi.org/10.1002/9781119612780.ch37openalex-snapshot

Immunosuppressive agents and monitoring in long‐term survivors

inferred← citeshttps://doi.org/10.1002/9781444391770.ch2openalex-snapshot

Pharmacology of transplantation

inferred← citeshttps://doi.org/10.1002/bdd.2206openalex-snapshot

The development of a population physiologically based pharmacokinetic model for mycophenolic mofetil and mycophenolic acid in humans using data from plasma, saliva, and kidney tissue

inferred← citeshttps://doi.org/10.1002/cpdd.1364openalex-snapshot

Effect of Tacrolimus Formulation (Prolonged‐Release vs Immediate‐Release) on Its Susceptibility to Drug‐Drug Interactions with St. John's Wort

inferred← citeshttps://doi.org/10.1002/cpdd.588openalex-snapshot

Clinical Pharmacokinetics and Drug‐Drug Interaction Potential for Coadministered SCY‐078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus

inferred← citeshttps://doi.org/10.1002/cpt.185openalex-snapshot

Direct‐acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now

inferred← citeshttps://doi.org/10.1002/cyto.a.22401openalex-snapshot

Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimus

inferred← citeshttps://doi.org/10.1002/jcla.24969openalex-snapshot

The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living‐donor Egyptian kidney transplanted patients

inferred← citeshttps://doi.org/10.1002/jcph.1118openalex-snapshot

Tacrolimus Population Pharmacokinetics and Multiple CYP3A5 Genotypes in Black and White Renal Transplant Recipients

inferred← citeshttps://doi.org/10.1002/jms.3909openalex-snapshot

First UHPLC–MS/MS method coupled with automated online SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co‐treated pediatric patients.

inferred← citeshttps://doi.org/10.1002/phar.1800openalex-snapshot

Pharmacologic Considerations for Solid Organ Transplant Recipients Who Become Pregnant

inferred← citeshttps://doi.org/10.1002/phar.2656openalex-snapshot

Race and sex associations with tacrolimus pharmacokinetics in stable kidney transplant recipients

inferred← citeshttps://doi.org/10.1002/phar.2848openalex-snapshot

Bayesian optimization of tacrolimus exposure in stable kidney transplant patients

inferred← citeshttps://doi.org/10.1002/smll.201703810openalex-snapshot

Highly Fluorescent Magnetic Nanobeads with a Remarkable Stokes Shift as Labels for Enhanced Detection in Immunoassays

inferred← citeshttps://doi.org/10.1007/978-1-4614-0008-0_6openalex-snapshot

Overview of Immunosuppressive Therapies in Renal Transplantation

inferred← citeshttps://doi.org/10.1007/978-1-4614-4454-1_35openalex-snapshot

Immunosuppression in the Renal Transplant Recipient

inferred← citeshttps://doi.org/10.1007/978-1-4939-1304-6_4openalex-snapshot

Pharmacometrics in Chronic Kidney Disease

inferred← citeshttps://doi.org/10.1007/978-3-319-05543-5_20-1openalex-snapshot

Immunology of Liver Transplantation

inferred← citeshttps://doi.org/10.1007/978-3-319-05543-5_20-2openalex-snapshot

Immunology of Liver Transplantation

inferred← citeshttps://doi.org/10.1007/978-3-319-07209-8_20openalex-snapshot

Immunology of Liver Transplantation

inferred← citeshttps://doi.org/10.1007/978-3-319-07284-5_32openalex-snapshot

Immunosuppression: Induction, Maintenance, and Steroid Avoidance Protocols

inferred← citeshttps://doi.org/10.1007/978-3-319-08049-9_32-1openalex-snapshot

Immunosuppression: Induction, Maintenance, and Steroid Avoidance Protocols

inferred← citeshttps://doi.org/10.1007/978-3-319-33280-2_23-1openalex-snapshot

Chronic Immunosuppression Medications

inferred← citeshttps://doi.org/10.1007/978-3-319-58054-8_23openalex-snapshot

Chronic Immunosuppression Medications

inferred← citeshttps://doi.org/10.1007/s00228-013-1584-7openalex-snapshot

Importance of hematocrit for a tacrolimus target concentration strategy

inferred← citeshttps://doi.org/10.1007/s00228-018-2558-6openalex-snapshot

Effects of clotrimazole on tacrolimus pharmacokinetics in patients with heart transplants with different CYP3A5 genotypes

inferred← citeshttps://doi.org/10.1007/s00467-014-2813-8openalex-snapshot

Therapeutic drug monitoring in pediatric renal transplantation

inferred← citeshttps://doi.org/10.1007/s00467-018-4117-xopenalex-snapshot

The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients

inferred← citeshttps://doi.org/10.1007/s00580-014-1987-6openalex-snapshot

The effect of CYP3A5 polymorphism on cyclosporine plasma level in Egyptian renal transplant recipients

inferred← citeshttps://doi.org/10.1007/s11096-014-9959-0openalex-snapshot

Therapeutic monitoring of pediatric renal transplant patients with conversion to generic cyclosporin

inferred← citeshttps://doi.org/10.1007/s11904-014-0212-1openalex-snapshot

Drug Interactions and Antiretroviral Drug Monitoring

inferred← citeshttps://doi.org/10.1007/s12185-019-02682-2openalex-snapshot

T-cell large granular lymphocyte leukemia in solid organ transplant recipients: case series and review of the literature

inferred← citeshttps://doi.org/10.1007/s12185-020-02986-8openalex-snapshot

Intrapatient variability in concentration/dose ratio of tacrolimus predicts transplant-associated thrombotic microangiopathy

inferred← citeshttps://doi.org/10.1007/s13318-014-0184-yopenalex-snapshot

Gender-dependent predictable pharmacokinetic method for tacrolimus exposure monitoring in kidney transplant patients

inferred← citeshttps://doi.org/10.1007/s13318-025-00942-7openalex-snapshot

Comparison of Machine Learning Algorithms and Bayesian Estimation in Predicting Tacrolimus Concentration in Tunisian Kidney Transplant Patients During the Early Post-Transplant Period

inferred← citeshttps://doi.org/10.1007/s40261-013-0153-2openalex-snapshot

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients

inferred← citeshttps://doi.org/10.1016/b978-0-12-820007-0.00013-1openalex-snapshot

Therapeutic drug monitoring

inferred← citeshttps://doi.org/10.1016/b978-0-323-05876-6.00097-6openalex-snapshot

Immunosuppressive Medications in Kidney Transplantation

inferred← citeshttps://doi.org/10.1016/b978-141605484-9.50089-7openalex-snapshot

Transplant Immunology and Immunosuppression

inferred← citeshttps://doi.org/10.1016/j.aca.2013.10.051openalex-snapshot

Ultra-fast cyclosporin A quantitation in whole blood by Laser Diode Thermal Desorption – Tandem Mass Spectrometry; comparison with High Performance Liquid Chromatography–Tandem Mass Spectrometry

inferred← citeshttps://doi.org/10.1016/j.apsb.2019.12.002openalex-snapshot

Hepatic and intestinal biotransformation gene expression and drug disposition in a dextran sulfate sodium-induced colitis mouse model

inferred← citeshttps://doi.org/10.1016/j.biopha.2018.03.054openalex-snapshot

Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations

inferred← citeshttps://doi.org/10.1016/j.bpg.2021.101757openalex-snapshot

Immunosuppressive drugs modes of action

inferred← citeshttps://doi.org/10.1016/j.ccell.2011.06.001openalex-snapshot

Pharmacology of Immunosuppressive Medications in Solid Organ Transplantation

inferred← citeshttps://doi.org/10.1016/j.cej.2024.150404openalex-snapshot

Evaluation of benefits and risks of immunosuppressive drugs in biomaterial-based neural progenitor cell transplantation for spinal cord injury repair

inferred← citeshttps://doi.org/10.1016/j.clinthera.2013.08.019openalex-snapshot

Personalized Tacrolimus Doses Determined by CYP3A5 Genotype for Induction and Maintenance Phases of Kidney Transplantation

inferred← citeshttps://doi.org/10.1016/j.cll.2018.11.003openalex-snapshot

Biomarkers in Solid Organ Transplantation

inferred← citeshttps://doi.org/10.1016/j.coph.2015.07.002openalex-snapshot

Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice

inferred← citeshttps://doi.org/10.1016/j.cpha.2015.09.012openalex-snapshot

Kidney Transplant for the Twenty-First Century

inferred← citeshttps://doi.org/10.1016/j.csbj.2023.07.038openalex-snapshot

Calcineurin B inhibits calcium oxalate crystallization, growth and aggregation via its high calcium-affinity property

inferred← citeshttps://doi.org/10.1016/j.ejpb.2016.01.011openalex-snapshot

Cyclosporine A lipid nanoparticles for oral administration: Pharmacodynamics and safety evaluation

inferred← citeshttps://doi.org/10.1016/j.ejps.2015.05.011openalex-snapshot

CYP3A4∗18B and CYP3A5∗3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects

inferred← citeshttps://doi.org/10.1016/j.ekir.2021.07.012openalex-snapshot

SARS-CoV-2 and Tacrolimus Blood Concentration in Kidney Transplant Recipients

inferred← citeshttps://doi.org/10.1016/j.genm.2012.10.003openalex-snapshot

Tacrolimus as a Part of Immunosuppressive Treatment in Kidney Transplantation Patients: Sex Differences

inferred← citeshttps://doi.org/10.1016/j.healun.2010.08.032openalex-snapshot

Age-specific complications among lung transplant recipients 60 years and older

inferred← citeshttps://doi.org/10.1016/j.healun.2018.05.005openalex-snapshot

Transplant phenomapping: A move toward personalized immunosuppression

inferred← citeshttps://doi.org/10.1016/j.healun.2024.10.026openalex-snapshot

Long short-term memory algorithm for personalized tacrolimus dosing: A simple and effective time series forecasting approach post-lung transplantation

inferred← citeshttps://doi.org/10.1016/j.hkjn.2011.09.007openalex-snapshot

Clinical experience of conversion from twice-daily standard-release tacrolimus to once-daily prolonged-release tacrolimus in stable renal transplant recipients

inferred← citeshttps://doi.org/10.1016/j.jaad.2016.06.014openalex-snapshot

From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis

inferred← citeshttps://doi.org/10.1016/j.jaad.2024.03.008openalex-snapshot

Full Guidelines—From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis

inferred← citeshttps://doi.org/10.1016/j.jconrel.2016.01.056openalex-snapshot

Reformulating cyclosporine A (CsA): More than just a life cycle management strategy

inferred← citeshttps://doi.org/10.1016/j.legalmed.2013.12.003openalex-snapshot

Fatal water intoxication during olanzapine treatment: A case report

inferred← citeshttps://doi.org/10.1016/j.mce.2012.10.030openalex-snapshot

The immunosuppressive agents rapamycin, cyclosporin A and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipose tissue

inferred← citeshttps://doi.org/10.1016/j.nefro.2025.501411openalex-snapshot

Rationalized immunosuppressant dosing in kidney transplantation: Mycophenolate mofetil AUC monitoring and key updates on tacrolimus exposure

inferred← citeshttps://doi.org/10.1016/j.nefroe.2026.501411openalex-snapshot

Rationalized immunosuppressant dosing in kidney transplantation: Mycophenolate mofetil AUC monitoring and key updates on tacrolimus exposure

inferred← citeshttps://doi.org/10.1016/j.nutres.2009.08.003openalex-snapshot

Select phytochemicals suppress human T-lymphocytes and mouse splenocytes suggesting their use in autoimmunity and transplantation

inferred← citeshttps://doi.org/10.1016/j.phrs.2013.06.003openalex-snapshot

Opportunity to monitor immunosuppressive drugs in peripheral blood mononuclear cells: Where are we and where are we going?

inferred← citeshttps://doi.org/10.1016/j.phrs.2016.07.027openalex-snapshot

Intra-cellular immunosuppressive drugs monitoring: A step forward towards better therapeutic efficacy after organ transplantation?

inferred← citeshttps://doi.org/10.1016/j.revmed.2022.03.343openalex-snapshot

Intérêt des dosages pharmacologiques d’immunosuppresseurs et immunomodulateurs dans la prise en charge des maladies autoimmunes

inferred← citeshttps://doi.org/10.1016/j.taap.2020.115000openalex-snapshot

Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant

inferred← citeshttps://doi.org/10.1016/j.taap.2020.115245openalex-snapshot

Dosing algorithm for Tacrolimus in Tunisian Kidney transplant patients: Effect of CYP 3A4*1B and CYP3A4*22 polymorphisms

inferred← citeshttps://doi.org/10.1016/j.transproceed.2008.07.070openalex-snapshot

De Novo Sirolimus-Based Regimen in Thai Renal Transplant Recipients

inferred← citeshttps://doi.org/10.1016/j.transproceed.2009.06.204openalex-snapshot

Monitoring of C0 and C2 Blood Concentrations of Cyclosporine on the Roche Hitachi 902 Analyzer

inferred← citeshttps://doi.org/10.1016/j.transproceed.2011.01.060openalex-snapshot

Is the Lower Cyclosporine Concentration at 2 Hours After Dosing Safe in Kidney Transplant Recipients?

inferred← citeshttps://doi.org/10.1016/j.transproceed.2011.08.105openalex-snapshot

Efficacy and Safety of Changing From Cyclosporine C0 to C2 Monitoring in Stable Recipients Following Renal Transplantation: A Prospective Cohort Study

inferred← citeshttps://doi.org/10.1016/j.transproceed.2016.03.043openalex-snapshot

Sublingual Tacrolimus in Liver Transplantation: A Valid Option?

inferred← citeshttps://doi.org/10.1016/j.transproceed.2018.02.108openalex-snapshot

No Significant Influence of Reduced Initial Tacrolimus Dose on Risk of Underdosing and Early Graft Function in Older and Overweight Kidney Transplant Recipients

inferred← citeshttps://doi.org/10.1016/j.transproceed.2019.11.003openalex-snapshot

Long-Term Kidney Transplant Outcomes: Role of Prolonged-Release Tacrolimus

inferred← citeshttps://doi.org/10.1016/j.trim.2014.05.002openalex-snapshot

Focus on mTOR inhibitors and tacrolimus in renal transplantation: Pharmacokinetics, exposure–response relationships, and clinical outcomes

inferred← citeshttps://doi.org/10.1016/j.trim.2023.101906openalex-snapshot

A prospective validation of a population pharmacokinetic model of tacrolimus in Tunisian kidney transplant patients

inferred← citeshttps://doi.org/10.1016/s1734-1140(10)70378-9openalex-snapshot

Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation

inferred← citeshttps://doi.org/10.1016/s2211-9698(20)75444-0openalex-snapshot

10.1016/s2211-9698(20)75444-0

inferred← citeshttps://doi.org/10.1038/clpt.2011.130openalex-snapshot

In Vivo CYP3A Activity Is Significantly Lower in Cyclosporine-Treated as Compared With Tacrolimus-Treated Renal Allograft Recipients

inferred← citeshttps://doi.org/10.1038/clpt.2012.109openalex-snapshot

In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients

inferred← citeshttps://doi.org/10.1038/clpt.2012.84openalex-snapshot

Time-Varying Belatacept Exposure and Its Relationship to Efficacy/Safety Responses in Kidney-Transplant Recipients

inferred← citeshttps://doi.org/10.1038/kisup.2011.14openalex-snapshot

Pharmacogenetics of tacrolimus: ready for clinical translation?

inferred← citeshttps://doi.org/10.1038/s41598-017-02140-1openalex-snapshot

Tacrolimus Blood Level Fluctuation Predisposes to Coexisting BK Virus Nephropathy and Acute Allograft Rejection

inferred← citeshttps://doi.org/10.1038/s41598-019-47876-0openalex-snapshot

Model based development of tacrolimus dosing algorithm considering CYP3A5 genotypes and mycophenolate mofetil drug interaction in stable kidney transplant recipients

inferred← citeshttps://doi.org/10.1038/s41598-022-07574-wopenalex-snapshot

Immunogenicity of ChAdOx1 nCoV-19 vaccine after a two-dose inactivated SARS-CoV-2 vaccination of dialysis patients and kidney transplant recipients

inferred← citeshttps://doi.org/10.1038/s41598-022-14317-4openalex-snapshot

Tacrolimus dose adjustment is not necessary in dose to dose conversion from a twice daily to a prolonged release once daily dose form

inferred← citeshttps://doi.org/10.1038/s41598-022-25445-2openalex-snapshot

Calcineurin inhibitors’ impact on cardiovascular and renal function, a descriptive study in lung transplant recipients from the North of Spain

inferred← citeshttps://doi.org/10.1053/j.ackd.2019.08.006openalex-snapshot

The Many Faces of Calcineurin Inhibitor Toxicity—What the FK?

inferred← citeshttps://doi.org/10.1080/10837450.2024.2448625openalex-snapshot

Drug-silica-cellulose ternary matrix for the oral delivery of Cyclosporine A: in vitro and in vivo evaluation

inferred← citeshttps://doi.org/10.1080/14622416.2024.2370761openalex-snapshot

Pharmacogenetics of Calcineurin inhibitors in kidney transplant recipients: the African gap. A narrative review

inferred← citeshttps://doi.org/10.1080/17512433.2024.2354276openalex-snapshot

Therapeutic drug monitoring in kidney and liver transplantation: current advances and future directions

inferred← citeshttps://doi.org/10.1089/jop.2024.0165openalex-snapshot

Tacrolimus 0.1% Ophthalmic Suspension: Corneal and Intraocular Penetration Study

inferred← citeshttps://doi.org/10.1089/neu.2009.1012openalex-snapshot

Safety and Tolerability of Cyclosporin A in Severe Traumatic Brain Injury Patients: Results from a Prospective Randomized Trial

inferred← citeshttps://doi.org/10.1093/chromsci/bmaf037openalex-snapshot

Simultaneous Measurement of Mycophenolic Acid with Other Immunosuppressants in Whole Blood and Plasma by Using Liquid Chromatography–Tandem Mass Spectrometry

inferred← citeshttps://doi.org/10.1093/ndt/gfaa063openalex-snapshot

Acute kidney injury in renal transplant recipients undergoing cardiac surgery

inferred← citeshttps://doi.org/10.1093/rpsppr/rqae016openalex-snapshot

Pattern of CYP3A5 and MDR-1 single-nucleotide polymorphism and its impact on Tacrolimus levels and clinical outcomes in living renal allograft recipient

inferred← citeshttps://doi.org/10.1097/fpc.0000000000000296openalex-snapshot

The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation

inferred← citeshttps://doi.org/10.1097/fpc.0000000000000516openalex-snapshot

Effect of CYP3A4*22, CYP3A5*3 and POR*28 genetic polymorphisms on calcineurin inhibitors dose requirements in early phase renal transplant patients

inferred← citeshttps://doi.org/10.1097/fpc.0b013e3283636856openalex-snapshot

A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients

inferred← citeshttps://doi.org/10.1097/fpc.0b013e328364db84openalex-snapshot

PharmGKB summary

inferred← citeshttps://doi.org/10.1097/ftd.0000000000000094openalex-snapshot

Transplant Patient Classification and Tacrolimus Assays

inferred← citeshttps://doi.org/10.1097/ftd.0000000000000266openalex-snapshot

Pretransplant Tacrolimus Dose Requirements Predict Early Posttransplant Dose Requirements in Blood Group AB0-Incompatible Kidney Transplant Recipients

inferred← citeshttps://doi.org/10.1097/ftd.0000000000000269openalex-snapshot

Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice

inferred← citeshttps://doi.org/10.1097/ftd.0000000000000299openalex-snapshot

Prospective Randomized Trial Investigating the Influence of Pharmaceutical Care on the Intra-Individual Variability of Tacrolimus Concentrations Early After Kidney Transplant: Erratum

inferred← citeshttps://doi.org/10.1097/ftd.0000000000000305openalex-snapshot

Prediction of Fat-Free Mass in Kidney Transplant Recipients

inferred← citeshttps://doi.org/10.1097/ftd.0000000000000313openalex-snapshot

Therapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure–Response Relationships in Renal Transplant Patients

inferred← citeshttps://doi.org/10.1097/ftd.0000000000000317openalex-snapshot

Validation of a 2-Point Limited Sampling Strategy to Predict the Tacrolimus Area-Under-the-12-Hour-Curve in Kidney Transplant Recipients

inferred← citeshttps://doi.org/10.1097/ftd.0000000000000331openalex-snapshot

Evaluation of the New Siemens Tacrolimus Assay on the Dimension EXL Integrated Chemistry System Analyzer: Comparison With an Ultra-Performance Liquid Chromatography–Tandem Mass Spectrometry Method

inferred← citeshttps://doi.org/10.1097/ftd.0000000000000364openalex-snapshot

A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation

inferred← citeshttps://doi.org/10.1097/ftd.0000000000000442openalex-snapshot

Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia

inferred← citeshttps://doi.org/10.1097/ftd.0000000000000542openalex-snapshot

Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation

inferred← citeshttps://doi.org/10.1097/ftd.0000000000000780openalex-snapshot

Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel

inferred← citeshttps://doi.org/10.1097/ftd.0000000000000828openalex-snapshot

Tacrolimus Bayesian Dose Adjustment in Pediatric Renal Transplant Recipients

inferred← citeshttps://doi.org/10.1097/ftd.0b013e318198d092openalex-snapshot

Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference

inferred← citeshttps://doi.org/10.1097/ftd.0b013e3181aa36cdopenalex-snapshot

New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation

inferred← citeshttps://doi.org/10.1097/ftd.0b013e3181eb8442openalex-snapshot

Apparent Elevation of Cyclosporine Whole Blood Concentrations in a Renal Allograft Recipient

inferred← citeshttps://doi.org/10.1097/ftd.0b013e318210e6d0openalex-snapshot

Monitoring of Nuclear Factor of Activated T-Cell-Regulated Gene Expression in De Novo and Long-Term Liver Transplant Recipients Treated With Cyclosporine A

inferred← citeshttps://doi.org/10.1097/ftd.0b013e318285e779openalex-snapshot

Lessons From Routine Dose Adjustment of Tacrolimus in Renal Transplant Patients Based on Global Exposure

inferred← citeshttps://doi.org/10.1097/md.0000000000001315openalex-snapshot

Association of Extrarenal Adverse Effects of Posttransplant Immunosuppression With Sex and ABCB1 Haplotypes

inferred← citeshttps://doi.org/10.1097/md.0000000000021010openalex-snapshot

Evaluation of cell-mediated immune response by QuantiFERON Monitor Assay in kidney transplant recipients presenting with infective complications

inferred← citeshttps://doi.org/10.1097/mpa.0b013e318239c6e5openalex-snapshot

Cyclosporin A, But Not FK506, Induces Osmotic Lysis of Pancreas Zymogen Granules, Intra-Acinar Enzyme Release, and Lysosome Instability by Activating K+ Channel

inferred← citeshttps://doi.org/10.1097/rhu.0000000000001429openalex-snapshot

Refractory, Recurrent Idiopathic Pulmonary Capillaritis Successfully Treated With Tacrolimus

inferred← citeshttps://doi.org/10.1097/tp.0000000000001651openalex-snapshot

Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients

inferred← citeshttps://doi.org/10.1097/tp.0000000000002918openalex-snapshot

The First Asian Kidney Transplantation Prediction Models for Long-term Patient and Allograft Survival

inferred← citeshttps://doi.org/10.1097/tp.0000000000003660openalex-snapshot

Unraveling the Genomic Architecture of the CYP3A Locus and ADME Genes for Personalized Tacrolimus Dosing

inferred← citeshttps://doi.org/10.1097/tp.0000000000004926openalex-snapshot

Pharmacomicrobiomics: Immunosuppressive Drugs and Microbiome Interactions in Transplantation

inferred← citeshttps://doi.org/10.1097/tp.0b013e3181afe9e7openalex-snapshot

Pharmacogenetics of Calcineurin Inhibitors in Renal Transplantation

inferred← citeshttps://doi.org/10.1097/tp.0b013e3181e9fedaopenalex-snapshot

Reduced C0 Concentrations and Increased Dose Requirements in Renal Allograft Recipients Converted to the Novel Once-Daily Tacrolimus Formulation

inferred← citeshttps://doi.org/10.1097/tp.0b013e3181ff4f7fopenalex-snapshot

Factors Increasing Quantitative Interstitial Fibrosis From 0 hr to 1 Year in Living Kidney Transplant Patients Receiving Tacrolimus

inferred← citeshttps://doi.org/10.1097/tp.0b013e318250fc62openalex-snapshot

Inhibitory Effect of Tacrolimus on p38 Mitogen-Activated Protein Kinase Signaling in Kidney Transplant Recipients Measured by Whole-Blood Phosphospecific Flow Cytometry

inferred← citeshttps://doi.org/10.1097/tp.0b013e3182a203bdopenalex-snapshot

OSAKA Trial

inferred← citeshttps://doi.org/10.1097/txd.0000000000001439openalex-snapshot

Does the Tacrolimus Trough Level Adequately Predict Drug Exposure in Patients Requiring a High Tacrolimus Dose?

inferred← citeshttps://doi.org/10.1109/sensors52175.2022.9967265openalex-snapshot

Toward an Aptasensor for Monitoring of Tacrolimus

inferred← citeshttps://doi.org/10.1111/ajt.14500openalex-snapshot

Voriconazole and squamous cell carcinoma after lung transplantation: A multicenter study

inferred← citeshttps://doi.org/10.1111/ajt.16250openalex-snapshot

Cyclosporine and COVID-19: Risk or favorable?

inferred← citeshttps://doi.org/10.1111/ajt.16867openalex-snapshot

SARS-CoV-2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study)

inferred← citeshttps://doi.org/10.1111/ajt.17151openalex-snapshot

An additional dose of viral vector COVID-19 vaccine and mRNA COVID-19 vaccine in kidney transplant recipients: A randomized controlled trial (CVIM 4 study)

inferred← citeshttps://doi.org/10.1111/bcp.12703openalex-snapshot

Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit

inferred← citeshttps://doi.org/10.1111/bcp.13811openalex-snapshot

The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients

inferred← citeshttps://doi.org/10.1111/ctr.13338openalex-snapshot

Immunophenotypic profile and clinical outcome of monoclonal B‐cell lymphocytosis in kidney transplantation

inferred← citeshttps://doi.org/10.1111/ctr.13727openalex-snapshot

Determining the conversion ratios for oral versus sublingual administration of tacrolimus in solid organ transplant recipients

inferred← citeshttps://doi.org/10.1111/ctr.15460openalex-snapshot

The Number of Episodes of Subtherapeutic Tacrolimus Blood Level Is Independently Associated With Reduced Kidney Graft Survival

inferred← citeshttps://doi.org/10.1111/ctr.70633openalex-snapshot

Planning Intermittent CalciNeurin Inhibitor Controls—The piCNIc Retrospective Cohort Study

inferred← citeshttps://doi.org/10.1111/cts.12990openalex-snapshot

Limited sampling strategies for estimation of tacrolimus exposure in kidney transplant recipients receiving extended‐release tacrolimus preparation

inferred← citeshttps://doi.org/10.1111/cts.70370openalex-snapshot

Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stable Black and White Kidney Transplant Recipients

inferred← citeshttps://doi.org/10.1111/imj.14043openalex-snapshot

Weight‐based tacrolimus trough concentrations post liver transplant

inferred← citeshttps://doi.org/10.1111/j.1399-0012.2011.01417.xopenalex-snapshot

KCNQ1 gene variants and risk of new‐onset diabetes in tacrolimus‐treated renal‐transplanted patients

inferred← citeshttps://doi.org/10.1111/j.1399-3046.2010.01354.xopenalex-snapshot

Pharmacodynamic monitoring of cyclosporine A by NFAT‐regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients

inferred← citeshttps://doi.org/10.1111/j.1432-2277.2009.00965.xopenalex-snapshot

Falsely elevated whole-blood tacrolimus concentrations in a kidney-transplant patient: potential hazards

inferred← citeshttps://doi.org/10.1111/j.1440-1797.2009.01155.xopenalex-snapshot

Long‐term graft function with tacrolimus and cyclosporine in renal transplantation: Paired kidney analysis

inferred← citeshttps://doi.org/10.1111/jcpt.13753openalex-snapshot

Pharmacokinetic principles of dose adjustment of mTOR inhibitors in solid organ transplanted patients

inferred← citeshttps://doi.org/10.1111/jorc.12339openalex-snapshot

Body weight‐based initial dosing of tacrolimus in renal transplantation: Is this an ideal approach?

inferred← citeshttps://doi.org/10.1111/nep.12738openalex-snapshot

Low‐target tacrolimus in de novo standard risk renal transplant recipients: A single‐centre experience

inferred← citeshttps://doi.org/10.1111/nep.70268openalex-snapshot

Thai Transplant Care Practice Guideline on Immunosuppressive Therapy for Adult Kidney Transplantation

inferred← citeshttps://doi.org/10.1111/petr.13733openalex-snapshot

Efficacy and safety of three times daily dosing of tacrolimus in pediatric kidney transplantation patients: A single‐center comparative study

inferred← citeshttps://doi.org/10.1111/petr.70074openalex-snapshot

Precision Dosing, Therapeutic Drug Monitoring, and Clinical Pharmacokinetics in Pediatric Kidney Transplant Patients: Principles and Practice With Emphasis on Low‐ and Middle‐Income Countries

inferred← citeshttps://doi.org/10.1111/tri.12020openalex-snapshot

Calcineurin inhibitor dose-finding before kidney transplantation in HIV patients

inferred← citeshttps://doi.org/10.1111/tri.12934openalex-snapshot

Higher calcineurin inhibitor levels predict better kidney graft survival in patients with de novo donor-specific anti-HLA antibodies: a cohort study

inferred← citeshttps://doi.org/10.1136/bcr-2020-234839openalex-snapshot

Use of phenytoin for treatment of tacrolimus toxicity with superimposed sepsis

inferred← citeshttps://doi.org/10.1136/bmjopen-2017-016144openalex-snapshot

Impact of intrapatient variability (IPV) in tacrolimus trough levels on long-term renal transplant function: multicentre collaborative retrospective cohort study protocol

inferred← citeshttps://doi.org/10.1136/gut.2008.163527openalex-snapshot

Immunosuppression for liver transplantation

inferred← citeshttps://doi.org/10.1155/2018/4573452openalex-snapshot

Which Kidney Transplant Recipients Can Benefit from the Initial Tacrolimus Dose Reduction?

inferred← citeshttps://doi.org/10.1159/000493979openalex-snapshot

Tacrolimus Suppositories in Therapy-Resistant Ulcerative Proctitis

inferred← citeshttps://doi.org/10.1177/08971900221107841openalex-snapshot

Artificially Elevated Tacrolimus Concentrations Obtained From a Venous Catheter Previously Used for Tacrolimus Administration in a Pediatric Patient

inferred← citeshttps://doi.org/10.1177/08971900241248862openalex-snapshot

Evaluation of Tacrolimus Concentrations and Clinical Outcomes Between Extended and Immediate Release Formulations in Kidney Transplant

inferred← citeshttps://doi.org/10.1177/1078155218793709openalex-snapshot

Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor α therapy

inferred← citeshttps://doi.org/10.1177/1090820x13520448openalex-snapshot

Pyoderma Gangrenosum Following Breast Reduction: Treatment With Topical Tacrolimus and Steroids

inferred← citeshttps://doi.org/10.1177/1526924816667950openalex-snapshot

Impact of a Clinical Solid Organ Transplant Pharmacist on Tacrolimus Nephrotoxicity, Therapeutic Drug Monitoring, and Institutional Revenue Generation in Adult Kidney Transplant Recipients

inferred← citeshttps://doi.org/10.1177/1526924819873905openalex-snapshot

Comparison of Tacrolimus Starting Doses Based on CYP3A5 Phenotype or Genotype in Kidney Transplant Recipients

inferred← citeshttps://doi.org/10.1177/2058739219845155openalex-snapshot

The level of intracellular tacrolimus in T cell is affected by CD44 + ABCB1 + activities triggered by inflammation

inferred← citeshttps://doi.org/10.1177/875512251202800304openalex-snapshot

Belatacept Post Kidney Transplantation

inferred← citeshttps://doi.org/10.1186/s12882-018-1014-2openalex-snapshot

Impact of reduced exposure to calcineurin inhibitors on the development of de novo DSA: a cohort of non-immunized first kidney graft recipients between 2007 and 2014

inferred← citeshttps://doi.org/10.1186/s40780-025-00427-4openalex-snapshot

Effect of isavuconazole on the concentration of tacrolimus in a patient with genotype CYP3A5*1/*3: a case report

inferred← citeshttps://doi.org/10.1186/s43054-025-00416-0openalex-snapshot

Impact of combined CYP3A4 and CYP3A5 single- nucleotide polymorphisms on tacrolimus exposure and acute rejection in Egyptian pediatric kidney transplant recipients: single center experience

inferred← citeshttps://doi.org/10.12659/aot.908522openalex-snapshot

Tacrolimus Granules for Oral Suspension as Post-Transplant Immunosuppression in Routine Medical Practice in France: The OPTIMOD Study

inferred← citeshttps://doi.org/10.1287/ijoo.2018.0007openalex-snapshot

Data-Driven Percentile Optimization for Multiclass Queueing Systems with Model Ambiguity: Theory and Application

inferred← citeshttps://doi.org/10.1287/msom.2019.0797openalex-snapshot

Data-Driven Management of Post-transplant Medications: An Ambiguous Partially Observable Markov Decision Process Approach

inferred← citeshttps://doi.org/10.12968/bjon.2018.27.18.1059openalex-snapshot

Immunosuppression following organ transplantation. Part 2: complications and their management

inferred← citeshttps://doi.org/10.1515/amma-2015-0082openalex-snapshot

The Monitoring of Immunosuppressive Therapy with Tacrolimus in Patients with Kidney Transplant, Based on the Pharmacokinetic Criteria

inferred← citeshttps://doi.org/10.1515/cclm-2014-1195openalex-snapshot

ABCB1 (MDR-1) pharmacogenetics of tacrolimus in renal transplanted patients: a Next Generation Sequencing approach

inferred← citeshttps://doi.org/10.1515/cclm.2011.143openalex-snapshot

Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes

inferred← citeshttps://doi.org/10.1517/14656566.2011.552428openalex-snapshot

Current immunosuppressive treatment after kidney transplantation

inferred← citeshttps://doi.org/10.1556/oh.2012.29429openalex-snapshot

Special considerations in generic substitution of immunosuppressive drugs in transplantation

inferred← citeshttps://doi.org/10.1592/phco.31.11.1111openalex-snapshot

Generic Maintenance Immunosuppression in Solid Organ Transplant Recipients

inferred← citeshttps://doi.org/10.1592/phco.31.4.394openalex-snapshot

Belatacept: A Novel Biologic for Maintenance Immunosuppression After Renal Transplantation

inferred← citeshttps://doi.org/10.1681/asn.2008080819openalex-snapshot

ABCB1 Genotypes Predict Cyclosporine-Related Adverse Events and Kidney Allograft Outcome

inferred← citeshttps://doi.org/10.1681/asn.2009090930openalex-snapshot

Allograft Biopsies

inferred← citeshttps://doi.org/10.2146/ajhp110624openalex-snapshot

Current trends in immunosuppressive therapies for renal transplant recipients

inferred← citeshttps://doi.org/10.2146/ajhp140322openalex-snapshot

Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients

inferred← citeshttps://doi.org/10.2147/ijn.s90849openalex-snapshot

Lipid nanoparticles for cyclosporine A administration: development, characterization, and in vitro evaluation of their immunosuppression activity

inferred← citeshttps://doi.org/10.2147/pgpm.s107710openalex-snapshot

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment

inferred← citeshttps://doi.org/10.2147/tcrm.s16870openalex-snapshot

Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants

inferred← citeshttps://doi.org/10.2165/00126839-200809050-00004openalex-snapshot

Cinacalcet Does Not Affect the Activity of Cytochrome P450 3A Enzymes, a Metabolic Pathway for Common Immunosuppressive Agents

inferred← citeshttps://doi.org/10.2165/11317350-000000000-00000openalex-snapshot

Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I

showing the first 200 of 251

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.